Search Results 641-650 of 16118 for quinine

  1. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  2. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  3. Trigeminal neuralgia - Doctors and departments - Mayo Clinic

    Learn about this nerve condition that can jolt areas on the face with electric-shock-like pain.

  4. Doctors and departments - Mayo Clinic

    Mayo Clinic experts research and test new treatments for focal segmental glomerulosclerosis (FSGS) through the Mayo Nephrology Collaborative Group. As a Mayo ...

  5. Impact of Cannabinoids on Sleep Parameters in Patients Undergoing Sleep Studies - Mayo Clinic

    The overarching purpose of this study is to advance our understanding of how cannabinoids interact with sleep physiology, potentially offering insights into ...

  6. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  7. Hematology - Clinical trials

    Hematology — Learn about innovative diagnosis and treatment options for blood diseases, including cancers, at Mayo Clinic.

  8. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  9. Epilepsy - Doctors and departments - Mayo Clinic

    They include magnetic resonance imaging, subtraction ictal SPECT coregistered to MRI (SISCOM), electroencephalography, ketogenic diet, deep brain stimulation, ...

  10. First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors - Mayo Clinic

    TP-0903 is a novel oral inhibitor that targets AXL kinase. Preclinical studies have shown promising antitumor activity of TP-0903 as a single agent against a ...